Additionally, a study in bladder cancer has found that the ACE-Ang II-AT1 receptor axis in the local RAS promotes VEGF production in platinum-resistant tumors (Tanaka et al., 2011), whereas the RAS new branch ACE2-Ang-(1–7)-Mas axis could reduce the production of VEGF in drug-resistant tumors, thereby inhibiting angiogenesis, although the reversal of tumor resistance has not yet been reported. The gene discussed is AGTR1; the disease is neoplasm.